Is PCYC a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,999 people get PCYC articles and Market Currents by email alert.

Get email alerts on PCYC »

HEADLINES:

6 Superstars For Your Biotech Portfolio: John McCamant
Life Sciences Report • Fri, May 10 • 1 Comment
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 59 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Pharmacyclics Reports First Quarter 2013 Results

PR Newswire (May 1, 2013)
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call

PR Newswire (Apr 24, 2013)
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK

PR Newswire (Apr 18, 2013)
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study

PR Newswire (Apr 11, 2013)
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor

PR Newswire (Apr 8, 2013)
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration

PR Newswire (Apr 8, 2013)
The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1
Brian Nichols • Fri, Apr 5 • 4 Comments
Pharmacyclics, Inc. Prices Public Offering of Common Stock

PR Newswire (Mar 8, 2013)
Seeking Opportunity: Creating A Plan Of Investment Action
Brian Nichols • Fri, Mar 8 • 22 Comments
Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire (Mar 7, 2013)
Pharmacyclics, Part 4: Financial Projection And Stock Valuation
Bio Vantage • Mon, Feb 25
Pharmacyclics, Part 3: Financials And Its Partnership With Johnson And Johnson
Bio Vantage • Mon, Feb 25
Pharmacyclics, Part 2: How Much Revenue Could Ibrutinib Generate?
Bio Vantage • Mon, Feb 25 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Pharmacyclics, Part 4: Financial Projection And Stock Valuation
Bio Vantage • Mon, Feb 25
Pharmacyclics, Part 3: Financials And Its Partnership With Johnson And Johnson
Bio Vantage • Mon, Feb 25
Pharmacyclics, Part 2: How Much Revenue Could Ibrutinib Generate?
Bio Vantage • Mon, Feb 25 • 1 Comment
Pharmacyclics, Part 1: Can The Incredible Run Continue?
Bio Vantage • Mon, Feb 25
Don't Tune Out; Pharmacyclics' Move Higher Isn't Over Yet
PropThink • Thu, Feb 21 • 2 Comments
Pharmacyclics Valuation Jumps Over $1 Billion On Newest Developments
Brian L. Wilson • Tue, Feb 19 • 14 Comments
Pharmacyclics Is Ripe For A Major Correction
John Li • Sat, Feb 16 • 18 Comments
Backed By Large Pharma And Key Investors, Pharmacyclics Is Set To Climb Higher
PropThink • Mon, Feb 11 • 3 Comments
Pharmacyclics And Promising Advances In Leukemia Treatment
Peter Geschek • Thu, Dec 13, 2012 • 3 Comments
After The Bloodbath, Where Does Pharmacyclics Go From Here?
John Li • Wed, Nov 14, 2012 • 9 Comments
Pharmacyclics Inc.: A Stock Up 400% This Year, A $4 Billion Company
Qineqt • Wed, Jun 27, 2012 • 9 Comments
Pharmacyclics: Product Pipeline Overshadows Stock Market Influence
Prohost Biotech • Wed, Jun 20, 2012 • 2 Comments
Bulls See Pharmacyclics Outperforming Bears, But For How Long?
James Stocklasar Thomas Jr. • Fri, Jun 1, 2012
Pharmacyclics: When The Power Of A Pipeline Overshadows The Market's Influence On Value
Prohost Biotech • Fri, Feb 24, 2012 • 1 Comment
Watch For The Dips On Pharmacyclics
Jessica King Holden • Tue, Feb 14, 2012 • 2 Comments
Pharmacyclics Is Flying, But There Are Reasons To Be Wary
VFC's Stock House • Mon, Feb 13, 2012 • 21 Comments
Pharmacyclics' Sale Of Blood Cancer Drug To J&J Is A Big Deal
EP Vantage • Sun, Dec 11, 2011
Positive Pipeline News Boosts Pharmacyclics, But Increased Costs May Spur Public Offering
EP Vantage • Thu, Jun 16, 2011
Is Pharmacyclics Eying China?
ChinaBio Today • Sun, Feb 22, 2009
The Bull Case For Pharmacyclics (PCYC)
• Thu, Dec 22, 2005

6 Superstars For Your Biotech Portfolio: John McCamant
Life Sciences Report • Fri, May 10 • 1 Comment
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 59 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1
Brian Nichols • Fri, Apr 5 • 4 Comments
Seeking Opportunity: Creating A Plan Of Investment Action
Brian Nichols • Fri, Mar 8 • 22 Comments
Multiple Myeloma And Different Treatment Approaches
Carl Cachia • Sun, Feb 17 • 9 Comments
8 Biotech Growth Names: Greg Wade
Life Sciences Report • Fri, Feb 8 • 3 Comments
3 Stocks With Recent Intensive Insider Selling
Markus Aarnio • Mon, Jan 21 • 2 Comments
Investing In The Future Of Multiple Myeloma Treatment
Brian L. Wilson • Wed, Jan 16 • 10 Comments
Which Companies Are In Michael King's Oncology Wheelhouse?
Life Sciences Report • Sat, Jan 12 • 2 Comments
2012 All-Star Stock Derby: Who Really Won?
Rochelle Jenks • Thu, Jan 3 • 2 Comments
Biotechnology In 2012: The Best Performing Industry
Ryan's View • Tue, Dec 4, 2012
Biotech Weekend Recap: Important Developments And Big Releases
Brian L. Wilson • Sun, Nov 11, 2012 • 3 Comments
VIX - Options Volatility Sonar: Monday Recap
Erick McKitterick • Mon, Nov 5, 2012
The Over/Under 'Value' Stock Shootout
Erick McKitterick • Mon, Nov 5, 2012 • 5 Comments
Out Of The Red And Into The Black: John McCamant On Investment In Blood Cancer Companies
Life Sciences Report • Thu, Oct 25, 2012
The Breakthrough At Northwest Biotherapeutics
Suresh Gupta • Thu, Oct 18, 2012 • 8 Comments

Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Pharmacyclics' CEO Discusses Q2 2013 Results - Earnings Call Transcript
Thu, Feb 14
Pharmacyclics' CEO Hosts ASH 2012 Recap Conference (Transcript)
Wed, Dec 12, 2012
Pharmacyclics Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Sep 6, 2012 • 5 Comments

Pharmacyclics Reports First Quarter 2013 Results

PR Newswire (May 1, 2013)
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call

PR Newswire (Apr 24, 2013)
Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK

PR Newswire (Apr 18, 2013)
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study

PR Newswire (Apr 11, 2013)
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor

PR Newswire (Apr 8, 2013)
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration

PR Newswire (Apr 8, 2013)
Pharmacyclics, Inc. Prices Public Offering of Common Stock

PR Newswire (Mar 8, 2013)
Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire (Mar 7, 2013)
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012

PR Newswire (Feb 14, 2013)
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration

PR Newswire (Feb 12, 2013)
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call

PR Newswire (Feb 7, 2013)
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting

PR Newswire (Dec 11, 2012)
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

PR Newswire (Dec 11, 2012)
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia

PR Newswire (Dec 8, 2012)
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting

PR Newswire (Nov 5, 2012)
Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

PR Newswire (Oct 15, 2012)
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments

PR Newswire (Sep 5, 2012)
Amgen, CBS Among Stocks Hitting 52-Week Highs Friday

at Fox Business (Aug 24, 2012)
Ebay, Toll Brothers Among Stocks Hitting 52-Week Highs Wednesday

at Fox Business (Aug 22, 2012)
Ebay, Toll Brothers Among Stocks Hitting 52-Week Highs Wednesday

at Fox Business (Aug 22, 2012)

PCYC vs. ETF Alternatives

Company Description

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our purpose is to create a profitable company by generating income from products we develop, license and... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:39 PM Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%). 3 Comments [Healthcare, On the Move]
Monday, May 13, 1:10 PM Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. 1 Comment [Healthcare, On the Move]
Thursday, May 2, 6:24 AM Pharmacyclics (PCYC): Q1 EPS of -$0.40 misses by $0.23. Revenue of $2.85M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
Thursday, April 11, 10:29 AM Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. 1 Comment [Healthcare, On the Move]
Monday, April 8, 7:19 AM Pharmacyclics' (PCYC) ibrutinib is granted a 3rd "Breakthrough Therapy Designation" by the FDA for treatment of certain patients with leukemia and lymphoma. (PR) 2 Comments [Healthcare]
Monday, March 25, 2:23 PM Pharmacyclics (PCYC +2.3%) gains today on the back of positive comments out of Credit Suisse, saying they're excited about the multi-billion dollar potential of its lymphoma/leukemia drug ibrutinib, and see the recent weakness in the shares as a possible entry point. The firm has a target price of $90, which looks attainable with a number of positive catalysts on the horizon. Comment! [Healthcare, On the Move]
Friday, March 8, 9:09 AM Pharmacyclics (PCYC) prices a previously announced public offering of 2.2M common shares, representing ~3.1% of common shares currently outstanding, at $94.20/share. After soaring 63% YTD, it's a smart and opportunistic capital raise, Jon Ogg writes. Shares -0.2% premarket. Comment! [Healthcare]
Tuesday, February 19, 12:31 PM Pharmacyclics (PCYC -4.4%) slips after being downgraded to Market Perform at Leerink Swann on the back of its recent run. Leerink says that a number of key catalysts have already been realized, and further upside beyond its current valuation while possible, will require stronger sales numbers from ibrutinib than what's currently available. The firm raised its price target on the stock to $97 from $80. Comment! [Healthcare, On the Move]
Thursday, February 14, 4:51 PM More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology. Comment! [Earnings]
Thursday, February 14, 4:33 PM Pharmacyclics (PCYC): FQ2 EPS of $0.62 beats by $0.31. Revenue of $57.9M (-20% Y/Y) beats by $11M. (PR) Comment! [Healthcare, Earnings, Breaking News]
Thursday, February 14, 12:10 AM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
Wednesday, February 13, 5:35 PM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
Wednesday, February 13, 8:26 AM The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies now plan to file for authorization of Ibrutinib by the end of the year. (PR) Comment! [Healthcare]
Wednesday, January 30, 12:11 PM Pharmacyclics (PCYC +1%) moves higher in today's trading on an upgrade to Buy at TheStreet, citing the company's strong financials, "robust" revenue growth and a respectable return on equity. Comment! [Healthcare, On the Move]
Tuesday, December 11, 2012, 11:41 AM Pharmacyclics (PCYC +5.5%) says that follow-up findings from an ongoing Phase II study suggest that its investigational oral agent ibrutinib resulted in "high and durable responses" and was generally well toleratedin patients with relapsed or refractory mantle cell lymphoma. Comment! [Healthcare, On the Move]

Tony Kau
$YHOO $INTC $PCYC bearish credit spread options trades this morning
Apr 23, 12:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's New Downgrades (3/21/13): $ACN, $ARG, $BID, $CLR, $CTSH, $EOG, $EWZ, $JPM, $OAS, $PCYC, $PH, $RKT, $SIAL, $TD, $TUMI, $UPS
Mar 21, 11:20 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Today's Potential Downgrades (3/18/13): , $ILMN, $IOC, $LNKD, $MDCO, $MGA, $MLNX, $MON, $NOW, $OCN, $OII, $PCLN, $PCYC, $PG, $PII, $PLCE
Mar 19, 7:43 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

whitehead1
$PCYC has given investors one of the highest return in last 5 years. What other stock can give us this kind of return? name names here.
Mar 17, 1:19 PM
Reply (9)

• !Report Abuse
View all 9 replies
whitehead1: what do you think of TC? that one I think has good future long term. Watching this one for a while. I like your AERL idea not too much PPHM
Mar 17, 2:24 PM
• !Report Abuse
DaLatin: I buy PPHM every time it goes under a buck. Then I set a gtc sale in for a double and wait. Can't remember how many times it's hit.A bunch !
Mar 17, 2:33 PM
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
NASDAQ Stalls as Volume Finishes Higher http://bit.ly/VRUXCL $KORS $INVN $AAPL $PCYC $NTGR $BWLD
Feb 13, 1:48 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

miller14
$PCYC
12/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$PCYC near edge of the start of an upside gap fill watch 55.3 break
12/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch- $AMRN, $IMSC.PK, $LPTN, $PFE, $AZN, $TEV, $SGYP, $YUM, $JAZZ, $PCYC, $ONVO.PK, $CPST, http://bit.ly/TGh20x
12/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$PCYC could get a boost above 55 and a gap fill
11/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/kDzg Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40. $PCYC" $BMRN
11/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

whitehead1
$PCYC has given investors one of the highest return in last 5 years. What other stock can give us this kind of return? name names here.
Mar 17, 1:19 PM
Reply (9)

• !Report Abuse
View all 9 replies
whitehead1: what do you think of TC? that one I think has good future long term. Watching this one for a while. I like your AERL idea not too much PPHM
Mar 17, 2:24 PM
• !Report Abuse
DaLatin: I buy PPHM every time it goes under a buck. Then I set a gtc sale in for a double and wait. Can't remember how many times it's hit.A bunch !
Mar 17, 2:33 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
8 Stocks Breaking Down http://bit.ly/R39ma3 BTH PCYC MENT TIBX HAIN TRMB M SGEN
9/20/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: TIBX reported great
9/20/12
• !Report Abuse
Add a reply...

140 characters

emburns
PCYC all time high - see if it holds $70 for strength
9/4/12
Reply (1)

• !Report Abuse
View all 1 replies
emburns: Tomorrow's morning announcement will be interesting.
9/4/12
• !Report Abuse
Add a reply...

140 characters

Chimera Research Group
We are big believers in $PCYC, $MDVN, $INCY, $SGEN and more.
7/10/12
Reply (1)

• !Report Abuse
View all 1 replies
RyRy: still a believer in INCY? Why this huge sell off?
8/2/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
14 Stocks That Only Go Up http://bit.ly/QWidJf $AKRX ALXN AMT BIIB CHD CRI DTE MO PCYC SCL TJX V WEC WFM
7/2/12
Reply (4)

• !Report Abuse
View all 4 replies
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day.
7/26/12
• !Report Abuse
Ryan Mallory: SCL breaking some heavy support, good chance that sell-off is earnings related.
7/27/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Long PCYC at $56 http://bit.ly/LC9GNv
7/9/12
Reply (2)

• !Report Abuse
View all 2 replies
emburns: Should have picked up some - crossing 60 probably hit stop orders and caused that drop. Easy 4% trade.
7/9/12
• !Report Abuse
Ryan Mallory: that was my thoughts happened a few weeks ago and the same thing happened - which is why i jumped on it.
7/9/12
• !Report Abuse
Add a reply...

140 characters

emburns
No stopping PCYC... going parabolic
6/19/12
Reply (2)

• !Report Abuse
View all 2 replies
Bob de'Long: I just checked the chart: more hyperbole than parabolic
6/19/12
• !Report Abuse
emburns: hyperbolic?
6/20/12
• !Report Abuse
Add a reply...

140 characters

tradingblues1
PCYC is unstoppable!
6/7/12
Reply (5)

• !Report Abuse
View all 5 replies
tradingblues1: PCYC given an $80 price target by Bream Murray!!!! Thats more than double PCYC opened up at today! http://bit.ly/MiLEkL
6/8/12
• !Report Abuse
TruffelPig: wow
6/8/12
• !Report Abuse
Add a reply...

140 characters

talbano
PCYC- looks good on a pullback
2/13/12
Reply (1)

• !Report Abuse
View all 1 replies
talbano: Becareful with this one it has gone up 10pt in a month
2/13/12
• !Report Abuse
Add a reply...

140 characters

tradingblues1
$PCYC is soaring today...hitting new 52-week Highs.
1/24/12
Reply (1)

• !Report Abuse
View all 1 replies
Marketfriends: looking great!
1/24/12
• !Report Abuse
Add a reply...

140 characters

Jeff Pierce
Where are the leading stocks? http://twurl.nl/46zg2g $AKRX $PCYC $LTS
12/4/11
Reply (6)

• !Report Abuse
View all 6 replies
1980XLS-2.0: I have never traded or owned LNG, But have owned GLNG
12/4/11
• !Report Abuse
Ocean Man: I had LNG calls for a couple months. 2 days after they expired, LNG joined that list.
12/4/11
• !Report Abuse
Add a reply...

140 characters

PCYC Pharmacyclics, Inc.

PCYC

Pharmacyclics, Inc.